gsk glp 1 agonist Emerging Trends in the Development of GLP-1 Receptor Agonists Glucagon-like peptide-1 (GLP-1) receptor agonists
Description
Obesity leads to significant SM changes
Goodwin Cartwright, C
doi: 10.1038/s41591-025-04106-7
Alzheimers disease drug development pipeline: 2024
The review further highlights emergent research on "next-generation" therapies with weight-loss efficacy of up to about 24% in clinical trials, approaching weight-loss magnitudes reported in some surgical interventions
GLP-1 RAs not only ameliorate insulin resistance and microvascular injury [84], which are significant determinants of depression in T2DM, but also enhance dopamine metabolism and stimulate growth factor signaling pathways, suggesting potential neuroprotective functions [85,86]
